<!DOCTYPE HTML>

<html>
	
	<head><script src="/livereload.js?mindelay=10&amp;v=2&amp;port=61685&amp;path=livereload" data-no-instant defer></script>
	<title>Psychotherapy</title>
	<meta charset="utf-8" />
	<meta name="viewport" content="width=device-width, initial-scale=1, user-scalable=no" />
	<meta name="description" content="">
	<meta name="author" content="">
	
	<meta name="msapplication-TileColor" content="#da532c">
    <meta name="theme-color" content="#ffffff">	
    <link rel="apple-touch-icon" sizes="180x180" href="../../apple-touch-icon.png">
    <link rel="icon" type="image/png" sizes="32x32" href="../../favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="../../favicon-16x16.png">
    <link rel="manifest" href="../../site.webmanifest">
    <link rel="mask-icon" href="../../safari-pinned-tab.svg" color="#5bbad5">
	
	
	
	
	
	<link rel="stylesheet" href="../../css/main.css">
	
	
	
	<noscript><link rel="stylesheet" href="../../css/noscript.css" /></noscript>
	

	
	<link rel="stylesheet" href="//localhost:61685/css/fontawesome-all.min.css">

</head>


	<body class="is-preload">

		
		<div id="wrapper" class="divided">

  
<section class="banner style1 orient-left content-align-left image-position-right onload-image-fade-in onload-content-fade-right">
    <div class="content">
        <h1>Addictions</h1>
        <p class="major">How does brain become addicted and how to break the vicious cycle?</p>
        
        <ul class="actions stacked">
            <li><a href="../../topics/" class="button primary large wide smooth-scroll-middle">← Back to Topics</a></li>
        </ul>
    </div>

    
  <div class="image">
    <img src="../../images/bike.jpg" alt="" />
  </div>


</section>

  <section class="wrapper style2" style="text-align: justify;">
    
        <p style="text-align: justify;"><em>July 26, 2025</em></p>
      

      <p><em>To fully benefit from reading this article, I&rsquo;d highly recommend reading about the hormones first. Also, I don&rsquo;t claim to be an expert in neuroscience, so I heavily rely on various academic papers and books to understand the mechanics myself and to later translate them into human language.</em></p>
<h2 id="oxytocin">Oxytocin</h2>
<p>The Rat Park experiment.</p>
<h2 id="references">References</h2>
<p>Lewis, M. (2015). The desire.</p>
<p>Plotik, D. Psychodynamic.</p>
<p>Volkow, N. D., &amp; Morales, M. (2015). <em>The brain on drugs: from reward to addiction.</em> Cell, 162(4), 712–725. doi:10.1016/j.cell.2015.07.046.</p>
<p>McGregor, I. S., &amp; Bowen, M. T. (2012). <em>Breaking the loop: oxytocin as a potential treatment for drug addiction.</em> Hormones and Behavior, 61(3), 331–339. doi:10.1016/j.yhbeh.2011.12.00</p>
<p>Müller, C. P., &amp; Homberg, J. R. (2015). <em>The role of serotonin in drug use and addiction.</em> Behavioural Brain Research, 277, 146–192. doi:10.1016/j.bbr.2014.04.007.</p>
<p><strong>The addiction macro-circuit &amp; the “dark side”</strong></p>
<p>• <strong>Koob, G. F., &amp; Volkow, N. D. (2016). Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry.</strong></p>
<p><em>Definitive, schematic review of the three-stage addiction cycle (binge/intoxication → withdrawal/negative affect → preoccupation/craving) and the anti-reward/dysphoria systems.</em></p>
<p>• <strong>Volkow, N. D., Fowler, J. S., &amp; Wang, G. J. (2003). The addicted human brain: insights from imaging studies. J Clin Invest.</strong></p>
<p><em>PET imaging overview showing how repeated drug use reshapes dopamine signalling, frontal control, and motivation.</em></p>
<p>• <strong>Everitt, B. J., &amp; Robbins, T. W. (2016). Drug addiction: updating the neurobiology of compulsion. Annu Rev Psychol.</strong></p>
<p><em>Elegant explanation of how goal-directed drug taking “slides” into dorsal-striatal habits and compulsions.</em></p>
<p>⸻</p>
<p><strong>2) Striatal D2 receptor loss &amp; impaired control</strong></p>
<p>• <strong>Volkow, N. D., Wang, G.-J., Fowler, J. S., et al. (2002). Decreased dopamine D2 receptor availability is associated with reduced frontal metabolism in cocaine addiction. Synapse.</strong></p>
<p><em>Classic PET work linking lower D2 in striatum to weaker frontal (PFC) metabolism/control.</em></p>
<p>• <strong>Volkow, N. D., Wang, G.-J., Telang, F., et al. (2007). Low dopamine striatal D2 receptors are associated with prefrontal metabolism in obese subjects: possible contributing factors. NeuroImage.</strong></p>
<p><em>Extends the D2–PFC control story to compulsive overeating—useful trans-diagnostic perspective.</em></p>
<p>⸻</p>
<p><strong>3) Ventral → dorsal striatum shift (reward → habit)</strong></p>
<p>• <strong>Everitt, B. J., &amp; Robbins, T. W. (2005). Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat Neurosci Rev.</strong></p>
<p><em>Foundational synthesis on the accumbens (ventral) → dorsal striatum recruitment as drug use becomes a habit.</em></p>
<p>• <strong>Belin, D., Jonkman, S., Dickinson, A., Robbins, T. W., &amp; Everitt, B. J. (2009). Parallel and interactive learning processes within the basal ganglia: relevance for the understanding of addiction. Behav Brain Res.</strong></p>
<p><em>Animal data showing parallel goal-directed and habitual controllers and how drugs bias the system.</em></p>
<p>⸻</p>
<p><strong>4) Serotonin &amp; anxiety (5-HT1A as the “calming” brake)</strong></p>
<p>• <strong>Neumeister, A., Bain, E., Nugent, A. C., et al. (2004). Reduced serotonin type 1A receptor binding in social anxiety disorder. Arch Gen Psychiatry.</strong></p>
<p><em>PET evidence that less 5-HT1A availability tracks with more anxiety.</em></p>
<p>• <strong>Savitz, J., Lucki, I., &amp; Drevets, W. C. (2009). 5-HT1A receptor function in major depressive disorder. Prog Neurobiol.</strong></p>
<p><em>Meta-analytic style review; while focused on depression, it clarifies pre- vs postsynaptic 5-HT1A roles relevant to anxiety too.</em></p>
<p>• <strong>Harmer, C. J., &amp; Cowen, P. J. (2013). ‘It’s the way that you look at it’—a cognitive neuropsychological account of SSRI action in anxiety/depression. Br J Psychiatry.</strong></p>
<p><em>Explains how SSRIs shift emotional processing early, long before mood “catches up.”</em></p>
<p>⸻</p>
<p><strong>5) 5-HT2C (and other 5-HT receptors) restraining dopamine &amp; impulsivity</strong></p>
<p>• <strong>Di Matteo, V., Cacchio, M., Di Giulio, C., &amp; Esposito, E. (2002). Serotonin control of central dopaminergic function: focus on in vivo microdialysis studies. Prog Brain Res.</strong></p>
<p><em>Mechanistic review: 5-HT2C activation often suppresses accumbens dopamine and impulsivity.</em></p>
<p>• <strong>Higgins, G. A., &amp; Fletcher, P. J. (2003). Serotonin and drug reward: focus on 5-HT2C receptors. Eur J Pharmacol.</strong></p>
<p><em>Directly reviews the 5-HT2C “brake” on reward seeking and stimulant intake.</em></p>
<p>⸻</p>
<p><strong>6) Oxytocin: amygdala dampening &amp; social reward</strong></p>
<p>• <strong>Kirsch, P., Esslinger, C., Chen, Q., et al. (2005). Oxytocin modulates neural circuitry for social cognition and fear in humans. J Neurosci.</strong></p>
<p><em>Seminal fMRI paper: intranasal oxytocin reduces amygdala activation to fearful faces.</em></p>
<p>• <strong>Domes, G., Heinrichs, M., Glascher, J., et al. (2007). Oxytocin attenuates amygdala responses to emotional faces regardless of valence. Biol Psychiatry.</strong></p>
<p><em>Replicates and extends the amygdala-dampening story.</em></p>
<p>• <strong>Shahrokh, D. K., Zhang, T.-Y., Diorio, J., Gratton, A., &amp; Meaney, M. J. (2010). Oxytocin-dopamine interactions mediate variations in maternal behavior in the rat. Endocrinology.</strong></p>
<p><em>Animal evidence for oxytocin–dopamine crosstalk in the VTA–NAcc, relevant for “social reward” as a drug competitor.</em></p>
<p>• <strong>Bethlehem, R. A. I., Baron-Cohen, S., van Honk, J., Auyeung, B., &amp; Bos, P. A. (2014/2017). The oxytocin paradox. Front Behav Neurosci / Biol Psychiatry reviews.</strong></p>
<p><em>Nuanced: oxytocin doesn’t always “increase trust”—context, personality, and diagnosis matter.</em></p>
<p>⸻</p>
<p><strong>7) BNST vs amygdala: sustained anxiety vs phasic fear</strong></p>
<p>• <strong>Davis, M., Walker, D. L., Miles, L., &amp; Grillon, C. (2010). Phasic vs. sustained fear in rats and humans: role of the extended amygdala (BNST). Biol Psychiatry.</strong></p>
<p><em>The go-to paper separating amygdala (phasic fear) from BNST (sustained anxiety).</em></p>
<p>• <strong>Shackman, A. J., &amp; Fox, A. S. (2016). Contributions of the BNST to anxiety and threat monitoring. Trends Cogn Sci.</strong></p>
<p><em>Modern, integrative view on BNST as a sustained-threat hub.</em></p>
<p>⸻</p>
<p><strong>8) SSRIs: why the delay? (autoreceptors → postsynaptic effects)</strong></p>
<p>• <strong>Blier, P., &amp; de Montigny, C. (1999). Serotonin and drug-induced therapeutic responses in major depression, OCD and anxiety disorders. Neuropsychopharmacology.</strong></p>
<p><em>Classic explanation: raphe 5-HT1A autoreceptor desensitisation → more 5-HT reaches postsynaptic calming sites.</em></p>
<p>• <strong>Artigas, F. (2013/2017). Future directions for SSRI antidepressants: combining pharmacology with cognitive neuroscience. (various reviews).</strong></p>
<p><em>Updates the “autoreceptor desensitisation + emotional processing shift” story in humans.</em></p>
<p>⸻</p>
<p><strong>9) Endorphins, anti-reward, and opioids</strong></p>
<p>• <strong>Koob, G. F. (2014). The dark side of addiction: the horse appears to be white. Neuropsychopharmacology.</strong></p>
<p><em>Short, sharp piece on anti-reward (dynorphin/kappa, CRF) and why withdrawal feels so bad.</em></p>
<p>• <strong>Maldonado, R., Berrendero, F., Ozaita, A., &amp; Robledo, P. (2014). Neurochemical basis of addiction. In The Neurobiology of Brain and Behavioral Development.</strong></p>
<p><em>Broad, opioid system &amp; endorphins in addiction overview.</em></p>
<p>• <strong>Leknes, S., &amp; Tracey, I. (2008). A common neurobiology for pain and pleasure. Nat Rev Neurosci.</strong></p>
<p><em>Explains how opioid/endorphin circuits sit at the intersection of relief and reward—key for both anxiety relief and addiction maintenance.</em></p>
<p>⸻</p>
<p><strong>10) PFC control, dopamine, and stress</strong></p>
<p>• <strong>Robbins, T. W., &amp; Arnsten, A. F. T. (2009). The neuropsychopharmacology of fronto-executive function: monoamine modulation. Annu Rev Neurosci.</strong></p>
<p><em>Gold-standard review on how dopamine (and noradrenaline) tune PFC control—too little or too much both hurt.</em></p>
<p>• <strong>Arnsten, A. F. T. (2015). Stress weakens prefrontal networks: molecular insults to higher cognition. Nat Neurosci Rev.</strong></p>
<p><em>Shows how stress chemistry (CRF, catecholamines) collapses PFC top-down control, relevant for both anxiety and relapse.</em></p>
<p>⸻</p>
<p><strong>11) (Optional) Psychedelics &amp; MDMA—why they’re being tested</strong></p>
<p>• <strong>Mitchell, J. M., Bogenschutz, M., et al. (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled Phase 3 study. Nat Med.</strong></p>
<p><em>Demonstrates large, durable effects in PTSD—relevant to anxiety/addiction comorbidity and the oxytocin/serotonin surge model.</em></p>
<p>• <strong>Carhart-Harris, R. L., &amp; Friston, K. J. (2019). REBUS and the anarchic brain: toward a unified model of the brain action of psychedelics. Pharmacol Rev.</strong></p>
<p><em>Explains how 5-HT2A agonism may “relax” rigid priors, potentially useful for addiction and anxiety stuck patterns.</em></p>
  </section>

  
<footer class="wrapper style1 align-center">
    <div class="inner">
        <ul class="icons">
            <li><a target="_blank" href="https://www.linkedin.com/in/veronica-zvereva-3208b2bb" class="icon brands style2 fa-linkedin"><span class="label">LinkedIn</span></a></li>
            <li><a target="_blank" href="mailto:veronikaz.therapy@gmail.com" class="fav icon style2 fa-envelope"><span class="label">Email</span></a></li>
            <li><a target="_blank" href="https://www.facebook.com/profile.php?id=61582323029567" class="icon brands style2 fa-facebook-f"><span class="label">Facebook</span></a></li>
        </ul>
        <p>Hugo Story &copy; 2020 <a target="_blank" href="https://github.com/caressofsteel/">CaressOfSteel</a><span class="footerspacer icon fa-diamond"></span>
            Ported from <a target="_blank" href="https://html5up.net/uploads/demos/story/">Story</a> by HTML5UP<span class="footerspacer icon fa-diamond"></span>
            Images courtesy of <a target="_blank" href="https://unsplash.com">Unsplash</a></p>
            Photo by <a href="https://unsplash.com/@uns__nstudio?utm_source=unsplash&utm_medium=referral&utm_content=creditCopyText">Unseen Studio</a> on <a href="https://unsplash.com/photos/person-writing-on-brown-wooden-table-near-white-ceramic-mug-s9CC2SKySJM?utm_source=unsplash&utm_medium=referral&utm_content=creditCopyText">Unsplash</a>
            Photo by <a href="https://unsplash.com/@kaboompics?utm_source=unsplash&utm_medium=referral&utm_content=creditCopyText">Karolina Grabowska</a> on <a href="https://unsplash.com/photos/a-vase-and-some-books-H_eb_VfG2Ow?utm_source=unsplash&utm_medium=referral&utm_content=creditCopyText">Unsplash</a>
            Photo by <a href="https://unsplash.com/@mkhamilton?utm_source=unsplash&utm_medium=referral&utm_content=creditCopyText">MK Hamilton</a> on <a href="https://unsplash.com/photos/silver-round-pendant-on-brown-wooden-chair-1hqHz9YNHxU?utm_source=unsplash&utm_medium=referral&utm_content=creditCopyText">Unsplash</a>
</div>
</footer>


<script type="text/javascript" src="//localhost:61685/js/fontawesome-all.min.js"></script>


		
		</div>
		
		
		












<script src='../../js/bundle.min.js'></script>



	</body>
</html>